Impact of second-line treatment (2L T) in advanced pancreatic cancer (APDAC) patients (pts) receiving first line Nab-Paclitaxel (nab-P) + Gemcitabine (G): An Italian multicentre real life experience.
暂无分享，去创建一个
E. Vasile | D. Melisi | V. Zagonel | M. Milella | A. Zaniboni | F. Bergamo | E. Giommoni | P. Bertocchi | L. Foltran | F. Vita | A. Iop | S. Vecchiarelli | A. Passardi | A. Febbraro | M. Aloi | V. Vaccaro | M. Marco | G. Musettini | G. Re | G. Giordano